首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer
【24h】

Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer

机译:紫杉醇纳米制剂的新目标:三阴性乳腺癌的希望和炒作

获取原文
获取原文并翻译 | 示例
           

摘要

Triple negative breast cancer is defined as one of the utmost prevailing breast cancers worldwide, possessing an inadequate prognosis and treatment option limited to chemotherapy and radiotherapy, creating a challenge for researchers as far as developing a specific targeted therapy is concerned. The past research era has shown several promising outcomes for TNBC such as nano-formulations of the chemotherapeutic agents already used for the management of the malignant tumor. Taking a glance at paclitaxel nano formulations, it has been proven beneficial in several researches in the past decade; nevertheless its solubility is often a challenge to scientists in achieving success. We have henceforth discussed the basic heterogeneity of triple negative breast cancer along with the current management options as well as a brief outlook on pros and cons of paclitaxel, known as the most widely used chemotherapeutic agent for the treatment of the disease. We further analyzed the need of nanotechnology pertaining to the problems encountered with the current paclitaxel formulations available discussing the strategic progress in various nano-formulations till date taking into account the basic research strategies required in terms of solubility, permeability, physicochemical properties, active and passive targeting. A thorough review in recent advances in active targeting for TNBC was carried out whereby the various ligands which are at present finding its way into TNBC research such as hyaluronic acid, folic acid, transferrin, etc. were discussed. These ligands have specific receptor affinity to TNBC tumor cells hence can be beneficial for novel drug targeting approaches. Conversely, there are currently several novel strategies in the research pipeline whose targeting ligands have not yet been studied. Therefore, we reviewed upon the numerous novel receptor targets along with the respective nano-formulation aspects which have not yet been fully researched upon and could be exemplified as outstanding target strategies for TNBC which is currently an urgent requirement. (C) 2016 Elsevier Ltd. All rights reserved.
机译:三阴性乳腺癌被定义为世界上最普遍的乳腺癌之一,其预后和治疗选择仅限于化学疗法和放射疗法,这给研究人员带来了挑战,就其开发特定的靶向疗法而言。过去的研究时代已经显示出TNBC的一些有希望的成果,例如已经用于治疗恶性肿瘤的化学治疗剂的纳米制剂。看看紫杉醇的纳米配方,在过去十年中的多项研究中都证明了它的益处。但是,其溶解度通常是科学家取得成功的挑战。此后,我们讨论了三阴性乳腺癌的基本异质性以及当前的治疗方案,并对紫杉醇(被认为是治疗该疾病的最广泛使用的化学治疗剂)的优缺点进行了简要展望。我们进一步分析了与现有紫杉醇制剂所遇到的问题有关的纳米技术的需求,讨论了迄今为止各种纳米制剂的战略进展,并考虑了溶解性,渗透性,理化性质,主动和被动方面所需的基础研究策略定位。对TNBC主动靶向的最新进展进行了详尽的综述,从而讨论了目前正在TNBC研究中使用的各种配体,例如透明质酸,叶酸,转铁蛋白等。这些配体对TNBC肿瘤细胞具有特定的受体亲和力,因此对于新型药物靶向方法可能是有益的。相反,目前有几种新的策略正在研究中,其靶向配体尚未得到研究。因此,我们回顾了许多新颖的受体靶标以及各自的纳米制剂方面,这些方面尚未得到充分研究,并且可以作为目前迫切需要的TNBC的出色靶标策略加以举例说明。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号